“Embedded in Lupin is a formula for growth which fuels creativity, performance and innovation”
It was Dr. Desh Bandhu Gupta’s vision and passion which helped him grow a small dream into a large company with a global footprint.
The most advanced pharmaceutical product development
Developing new chemical entities for focused therapy areas
Producing quality medicines in areas of unmet needs
Producing high quality affordable and accessible biologics
Financial Result
Share Capital
Press Releases
Press Kit
BSE -
NSE -
Lupin Receives Approval for Rufinamide Oral Suspension
Mumbai, Baltimore, December 21, 2020: Lupin Limited (NSE: Lupin), global pharmaceutical company, announced today that it has received approval for its Rufinamide Oral Suspension, 40 mg/mL, from the United States Food and Drug Administration, to market a generic equivalent of Banzel® Oral Suspension, 40 mg/mL, of Eisai Inc.
Rufinamide Oral Suspension, 40 mg/mL is indicated for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in pediatric patients 1 year of age and older, and in adults.
Rufinamide Oral Suspension, 40 mg/ mL (RLD: Banzel®) had estimated annual sales of USD 124.5 million in the
U.S. (IQVIA MAT September 2020).
About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women’s health areas. Lupin is the 3rd largest pharmaceutical company in the U.S. by prescriptions and 5th in India by global revenues. The Company invests 9.6 % of its revenues on research and development.
Lupin has fifteen manufacturing sites, seven research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: www.twitter.com/LupinGlobal | LinkedIn: www.linkedin.com/company/lupin/ Facebook: www.facebook.com/LupinWorld/
For further information or queries please contact –
Head – Corporate Communications Email: shwetamunjal@lupin.com
Head – Investor Relations and M&A Email: arvindbothra@lupin.com
General Manager – Corporate Communications Email: manjirasharma@lupin.com
*Safe Harbor Statement
Banzel® is a registered trademark of Novartis AG Corporation.
